China Options For Takeda As It Pursues Emerging Markets Buy
Takeda’s recent revelation that it had set aside around $450m for a planned M&A transaction in an undisclosed emerging market has triggered speculation about where and how the company might spend its money. Might China be in the mix?
You may also be interested in...
Another Japanese company is building its Chinese presence through a local partnership, this time eye care specialist Santen, which is planning to link with a state-owned company in Chongqing.
Major Japanese innovator Eisai is moving into the Chinese generics sector through the acquisition of the small Chinese firm Liaoning TianYi Biological, in a move it says is designed to tap into strong projected market growth for such products in China.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.